INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 133 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2017. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $26,796,000 | +6.9% | 2,200,000 | 0.0% | 0.67% | -16.1% |
| Q4 2018 | $25,058,000 | -47.5% | 2,200,000 | 0.0% | 0.80% | -36.4% |
| Q3 2018 | $47,740,000 | +22.8% | 2,200,000 | 0.0% | 1.26% | +12.6% |
| Q2 2018 | $38,874,000 | -16.1% | 2,200,000 | 0.0% | 1.12% | -12.3% |
| Q1 2018 | $46,310,000 | +45.4% | 2,200,000 | 0.0% | 1.28% | +42.7% |
| Q4 2017 | $31,856,000 | -8.2% | 2,200,000 | 0.0% | 0.90% | -6.7% |
| Q3 2017 | $34,716,000 | +30.0% | 2,200,000 | +2.3% | 0.96% | +17.8% |
| Q2 2017 | $26,703,000 | -14.6% | 2,150,000 | +11.7% | 0.82% | -20.2% |
| Q1 2017 | $31,281,000 | +31.6% | 1,925,000 | +22.2% | 1.02% | +16.2% |
| Q4 2016 | $23,767,000 | +15.5% | 1,575,000 | +16.7% | 0.88% | +21.7% |
| Q3 2016 | $20,574,000 | -24.3% | 1,350,000 | +92.9% | 0.72% | -32.6% |
| Q2 2016 | $27,174,000 | – | 700,000 | – | 1.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |